STATUS: Recruiting

SPONSOR: Leiden University Medical Center
LEAD GROUP: DGOG
ENGOT Model: A
TITLE: A phase II study of tailored adjuvant therapy in Pole-mutated and p53-wildtype/NSMP early stage endometrial cancer (RAINBO BLUE & TAPER)
ClinicalTrials.gov ID: NCT05255653    
MaNGO sites (click to see the list)     

STATUS: Recruiting

SPONSOR: Karyopharm Therapeutics Inc.
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
ClinicalTrials.gov ID: NCT05611931
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: AGO Study Group
LEAD GROUP: AGO Study Group
ENGOT Model: A
TITLE: Evaluation of preoperative clinical and translation selection criteria for cytoreductive surgery in endometrial cancer . A retrospective multicenter trial with an accompanying translational Project. Surgical Treatment in Advanced and Recurrent Endometrial CAncer Management
ClinicalTrials.gov ID: to be defined
MaNGO sites (click to see the list)    

STATUS: Planned
SPONSOR: AstraZeneca

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan(T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer

ClinicalTrials.gov ID: NCT06989112

STATUS: Planned
SPONSOR: BioNTech SE

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer

ClinicalTrials.gov ID: NCT06340568

MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: Astrazeneca

LEAD GROUP:  AGO-austria
ENGOT Model: C
TITLE: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) 

ClinicalTrials.gov ID: NCT07044336

MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: MSD

LEAD GROUP: GTG-UK
ENGOT Model: C
TITLE: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer

ClinicalTrials.gov ID: NCT06952504

STATUS: Recruiting
SPONSOR: GSK GlaxoSmithKline

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A randomized, multicenter, open-label, Phase 3 study to evaluate GSK5733584 in comparison with chemotherapy in participants with recurrent endometrial cancer (BEHOLD-Endometrial01)

ClinicalTrials.gov ID: NCT07286331

STATUS: Planned
SPONSOR: Pfizer

LEAD GROUP: AGO
ENGOT Model: C
TITLE: An Interventional Phase 3, Open Label, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR Proficient Endometrial Cancer

ClinicalTrials.gov ID: NCT07578649

MaNGO sites (click to see the list)